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Abstract
Background: Lung cancers consist of four major types that and for clinical-pathological reasons are often divided
into two broad categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). All major
histological types of lung cancer are associated with smoking, although the association is stronger for SCLC and
squamous cell carcinoma than adenocarcinoma. To date, epidemiological studies have identified several
environmental, genetic, hormonal and viral factors associated with lung cancer risk. It has been estimated that
15-25% of human cancers may have a viral etiology. The human papillomavirus (HPV) is a proven cause of most
human cervical cancers, and might have a role in other malignancies including vulva, skin, oesophagus, head and
neck cancer. HPV has also been speculated to have a role in the pathogenesis of lung cancer. To validate the
hypothesis of HPV involvement in small cell lung cancer pathogenesis we performed a gene expression profile of
transgenic mouse model of SCLC induced by HPV-16 E6/E7 oncoproteins.
Methods: Gene expression profile of SCLC has been performed using Agilent whole mouse genome (4 × 44k)
representing ~ 41000 genes and mouse transcripts. Samples were obtained from two HPV16-E6/E7 transgenic
mouse models and from littermate’s normal lung. Data analyses were performed using GeneSpring 10 and the
functional classification of deregulated genes was performed using Ingenuity Pathway Analysis (Ingenuity
®
Systems, http://www.ingenuity.com).
Results: Analysis of deregulated genes induced by the expression of E6/E7 oncoproteins supports the hypothesis
of a linkage between HPV infection and SCLC development. As a matter of fact, comparison of deregulated genes
in our system and those in human SCLC showed that many of them are located in the Aryl Hydrocarbon Receptor
Signal transduction pathway.
Conclusions: In this study, the global gene expression of transgenic mouse model of SCLC induced by HPV-16
E6/E7 oncoproteins led us to identification of several genes involved in SCLC tumor development. Furthermore,
our study reveled that the Aryl Hydrocarbon Receptor Signaling is the primarily affected pathway by the E6/E7
oncoproteins expression and that this pathway is also deregulated in human SCLC. Our results provide the basis
for the development of new therapeutic approaches against human SCLC.
Background
Human papillomaviruses (HPVs) are a collection of
over 200 viruses that can infect humans. HPV is most
often spread through skin-to-skin contact, usually
sexually. Genital HPV infections are very common and
are sexually transmitted. Most HPV infections occur
without any symptoms and go away without any treat-
ment over the course of a few years. However, HPVs
infection sometimes persists for many years in the
host, either through the establishment of latent or
chronic infections, which can ultimately lead to cellular
transformation [1]. It is now well-established that high-
risk HPVs play a role in most cases of cervical cancer,
as well as many cases of vulvar, penile, and anal can-
cers [2,3]. HPV 16 and 18 have been identified not
only in gynecological carcinomas but also in tumors of
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oropharynx especially those occurring in young, non-
smoking women. Only a few of these viruses are con-
sidered the “cancer-causing” strains, most notably,
H P V1 6a n dH P V1 8[ 4 - 6 ] .
The possibility that HPV may play a role in the devel-
opment of lung cancer was first suggested by Syrjanen
in 1979 who described epithelial changes in bronchial
carcinomas closely resembling those of established HPV
lesions in the genital tract [7]. Since then, several studies
provided evidence of HPV 16 and 18 DNA in lung can-
cers, but there were inconsistency in the reported preva-
lence of infection by HPVs in patients with lung cancer
in different countries, with racial and geographic varia-
tions. In the United States, HPVs DNA is found in
about 20-25% of lung cancers [8]. The most common
strains found are HPV 16 and HPV 18, the same strains
that are commonly found in cervical cancer. More than
90% of lung cancer in Taiwanese females is not related
to cigarette smoking and 55% had HPV16/18 DNA
compared with 11% of non cancer control subjects.
Additionally HPV 16/18 DNA has been uniformly
detected in lung tumor cells but not in the adjacent
noninvolved lung tissue [9]. HPV 16/18 have been
detected in the blood of women with cervical infection
suggesting that HPV 16/18 can infect the lung through
hematic spread from infected sites [10].
A recent review summarizes the studies conducted to
establish the association between the presence of HPVs
and lung cancer [11]. HPVs detection rates in lung can-
cer are highly variable in the different studies published
from several countries, ranging from 0% to 79%. The
mean incidence of HPVs in lung cancer considering all
reviewed articles is 24.5%. While in Europe and in the
USA the average reported incidences is 17% and 15%,
respectively, the mean incidence of HPVs in Asian lung
cancer is 35.7%. The authors concluded that HPV may
be the second leading cause of lung cancer after cigar-
ette smoking.
Although studies of viral-related lung cancer have
been reported, the molecular mechanisms of this disease
remain unclear [12-14]. Therefore, an increase in
knowledge of factors promoting lung carcinogenesis, as
the infection with human papillomavirus, gains in
importance.
In this study we examined the gene expression profile
of previously described transgenic mouse model (CK5-
PAP-2303) of SCLC induced by HPV-16 E6/E7 onco-
proteins [15] and compared data with those obtained
from human tissue with SCLC.
The aim of our study was to identify molecular
mechanisms associated to SCLC development induced
by HPV 16 oncoproteins and in patients affected by
SCLC to validate our “in vivo” model and the derived
cell lines for the development and evaluation of new
anticancer molecules.
Methods
RNA purification, labelling and oligonucleotides
microarray hybridization
Lung tissues from 9-month-old wild-type and transgenic
mice, were homogenised in Qiazol solution (Qiagen) by
rotor-stator and RNA was extracted using RNeasy mini
kit from Qiagen according to manufacturer’sp r o t o c o l .
RNA samples were analyzed quantitatively and qualita-
tively by NanoDrop ND-1000 UV-Vis Spectrophot-
ometer (NanoDrop Technologies, Wilmington, DE) and
by Bioanalyzer (Agilent Technologies, Palo Alto, CA).
Only samples with R.I.N. (RNA Integrity Number) >8.0,
260/280 nm absorbance >1.8 and 260/230 absorbance
>2, were used for RNA labelling. Total RNA from lung
tumor and controls, was amplified in the presence of
cyanine-3/cyanine-5 labelled CTP using Agilent low
RNA Input Fluorescent Linear Amplification kit (Agilent
Technologies, Palo Alto, CA) according to manufac-
turer’s protocol. After labelling, targets were purified
using Qiagen’sR N e a s ym i n is p i nc o l u m nt or e m o v e
unincorporated dye-labelled nucleotides. The quality of
labelled targets was determined by calculating the
amount of cDNA produced, the pmoles of dye incorpo-
rated and the frequency of incorporation by NanoDrop.
Equal amounts of cRNAs (825 ng) from control
(labelled with Cy3) and from transgenic mouse (labelled
with Cy5) were mixed together and hybridized to the
microarray in a hybridization oven at 65°C for 17 hours
with rotation at 10 rpm. Gene expression profile of
transgenic SCLC has been performed using Agilent
whole mouse genome (4 × 44k) representing ~ 41000
genes and mouse transcripts. Samples were obtained
from two HPV16-E6/E7 transgenic mice and from 2 lit-
termate’s normal lung. For each sample were performed
the technical replicates.
After hybridization slides were washed with Gene
Expression Wash buffer 1 for 1 minute at room
temperature and Gene Expression Wash buffer 2 for
1 minute at 37°C. Finally to dry the slides and prevent
ozone degradation arrays were treated with the Stabili-
zation and Drying Solution (Agilent Technologies, Palo
Alto, CA) for 30 seconds at room temperature. After
wash the slides were scanned with the Agilent’sd u a l -
laser microarray scanner (G2565AA) and image data
were processed using Agilent Feature extraction soft-
ware (FE) (Agilent Technologies). This software calcu-
lates log ratios and p-values for valid features on each
array and provides a confidence measure of gene differ-
ential expression performing outlier removal and back-
ground subtraction. Furthermore, FE filters features that
are not positive and significant respect to background
Buonomo et al. Journal of Translational Medicine 2011, 9:2
http://www.translational-medicine.com/content/9/1/2
Page 2 of 11and/or saturated. FE was also used to perform linear
and LOWESS dye normalization to correct dye bias.
Microarray data analysis
The raw data and associated sample information were
loaded and processed by GeneSpring
® 10 (Agilent Tech-
nologies). Statistical analysis was performed using back-
ground-corrected mean signal intensities from each dye
channel. Microarray data were normalized using inten-
sity-dependent global normalization (LOWESS). Differ-
entially expressed RNAs were identified using a filtering
by the Benjamini and Hochberg False Discovery Rate
(p-Value < 0.05) to minimize selection of false positives.
Of the significantly differentially expressed RNA, only
those with greater than 2-fold increase or 2-fold
decrease in expression compared to the controls were
used for further analysis. All microarray data presented
in this manuscript are in accordance with MIAME
guidelines and have been deposited in the NCBI GEO
database (The Accession Number it is available by
referees).
Functional and network analyses of statistically signifi-
cant gene expression changes were performed using
Ingenuity Pathways Analysis (IPA) 8.0 (Ingenuity
® Sys-
tems, http://www.ingenuity.com). Analysis considered all
genes from the data set that met the 2-fold (p-value <
0.05) change cut-off and that were associated with biolo-
gical functions in the Ingenuity Pathways Knowledge
Base. For all analyses, Fisher’se x a c tt e s tw a su s e dt o
determine the probability that each biological function
assigned to the genes within each data set was due to
chance alone.
Histopathology
Transgenic and control lungs were removed, washed in
PBS and fixed with 4% buffered formaldehyde. Samples
were processed and paraffin-embedded. Sections were
stained with hematoxylin/eosin and observed with a
Zeiss light microscope.
Semiquantitative reverse transcriptase-PCR
Semiquantitative reverse transcriptase-PCR (RT-PCR)
was done essentially as previously described [16]. RNA
(2 μg/reaction) was used to generate cDNA and the
appropriate individual pairs of oligonucleotides (40
pmol/reaction) for the test genes were used to amplify
DNA from the cDNA. Semiquantitative PCR was done
by using 100 μL reaction volumes and taking 33 μL
aliquots at 25, 30, and 35 cycles. The expression of 18
S mRNA, which is ubiquitously expressed, was deter-
mined for each RNA sample to control for variations
in RNA quantity. Ten microliters of each reaction
were electrophoresed in a 1% agarose gel containing
ethidium bromide. The gel was then developed using
t h eG e l D o cX Rs y s t e m( B i o - Rad) and quantified using
Quantity One (Bio-Rad).
The Bioethics Committee of the University of Siena
approved all the experiments conducted on live animals.
All the experiments were performed in accordance with
guidelines and regulations.
Results
Gene expression profiles
To identify mechanisms associated with SCLC develop-
ment and its neuroendocrine differentiation associated
to E6/E7 oncoproteins expression, we analyzed the gene
expression profile of transgenic lung tumor through
microarrays. Experiments were performed on lung sam-
ples from two different transgenic animals compared to
normal lung tissue. To identify the differentially
expressed genes, using the criteria described in Materials
and Methods for Microarray data analysis, we found
5307 significantly deregulated genes. Among these 2242
genes were up-regulated and 3065 were downregulated.
Up and down regulated genes are reported in the addi-
tional file 1. For each gene the probe ID, fold change, p-
value, gene symbol, Gene Bank and description are
reported. Interestingly, among all the genes deregulated
by the E6/E7 co-expression, 116 genes are associated to
neurogenesis. The list of these genes is reported in addi-
tional file 2. These results support the hypothesis of a
possible role of E6 and E7 in the induction of neuroen-
docrine differentiation of SCLC. To confirm gene array
analysis data and to validate some genes involved in this
process, we performed semiquantitative RT-PCR using
RNA purified from transgenic lung tumour, from litter-
mate normal lung and from the PPAP9 cell line, estab-
lished from the transgenic lung tumour [16]. As shown
in Figure 1 Ascl1, Igf2, Scg2, Chga and Foxa2, consid-
ered reliable markers of neuroendocrine differentiation,
a r eu p - r e g u l a t e di nt i s s u ea n dc e l l sf r o mt u m o u r
induced by E6/E7 compared to normal lung. Further-
more Cav1 and Cav2 are down regulated, according to
previously published results showing a tumor suppressor
activity of Caveolin-1 and its down-regulation during
lung cancer development [17]. The relative direction of
expression was the same for both the RT-PCR and
microarray results. The primers used for RT-PCR are
reported in additional file 3.
The transgenic mice develop brochiogenic lung cancer
around 6 months of age, and the E6/E7 genes were effi-
ciently expressed in pre-neoplastic and neoplastic cells.
The transgenic mice lung tumors showed a progression
from in situ to invasive carcinoma and in a minor per-
centage brain, liver and pancreas metastases were
observed. Inactivation of p53 and pRB occurs in the
majority of neuroendocrine lung carcinomas in humans
and these observations strongly suggest that E6/E7
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transgenic model, through the inactivation of p53 and
pRB. The transgenic lung carcinoma progress to multi-
ple and bilateral tumors with histopathology and immu-
nophenotype closely mirroring human SCLC constituted
by small cells with a very high nucleus/cytoplasm ratio.
Histological examination of mice lungs showed the
occurrence of multiple dysplastic foci of clustering small
cells in the bronchial and bronchiolar mucosa as shown
in Figure 2. Furthermore intrapulmonary tumors aggres-
sively invade lung parenchyma and vessels and readily
metastasized to extra pulmonary sites, again very similar
to human SCLC. Moreover a subcutaneous injection of
two murine cell lines (PPAP9 and PPAP10), established
from the transgenic SCLC, form primary tumors as well
metastasis typical of the pattern seen in human SCLC
patients [16]. The histological and biological properties
of our model are overlapping to those of two other
described murine SCLC models, obtained using different
experimental approaches [18,19].
Human SCLC metastasizes early and widely and
u s u a l l yi ti sn o tt r e a t a b l eb ys u r g e r ym a k i n gt i s s u e
retrieval particularly difficult. Therefore the results
obtained in our experimental system were compared
with those available for human SCLC in Gene Expres-
sion Omnibus (GEO), a public functional genomics data
repository. We imported data files from GSE6044,
selecting five sets derived from human normal lung,
(GSM140185-GSM140189), and five sets from human
SCLC, (GSM140176-GSM140180) [20] and analyzed
data sets with GeneSpring 10. Of the 8793 genes exam-
ined, 561 were differentially expressed to a significant
degree (ANOVA, p < 0.05). Among these, 289 genes
were up-regulated and 272 were down-regulated. Genes
are listed in the additional file 4 reporting for each gene,
p r o b eI D ,t h ef o l dc h a n g e ,p - v a l u e ,g e n es y m b o l ,G e n e
Bank and description. The significant difference in the
number of deregulated genes from the two analyses is
associated with the different number of genes present in
the arrays, 44000 for the Agilent system and 8793 for
the Affymetrix platform. Hierarchical clustering of the
human differentially expressed genes according to their
expression patterns is reported in Figure 3. Genes up-
regulated in human SCLC are shown in red, down-regu-
lated genes are shown in green, while black bars indicate
genes that are expressed at similar levels in both. To
highlight the molecular mechanisms common to tumor
induced by E6/E7 oncoproteins and human SCLC, we
compared the results obtained in the two systems. We
identified 130 up- and 72-down regulated genes com-
mon to human SCLC and the E6/E7 induced lung
tumour. The list of genes is reported in the additional
file 5 showing for each gene, description, gene symbol,
family name, probe ID for transgenic mouse (Agilent),
probe ID for human SCLC (Affymetrix), the fold change
and relative p-values. To underline similarities among
samples and among genes, we overlaid the unsupervised
two-dimensional hierarchical clustering, obtained from
Figure 1 Confirmation of microarray data. RT-PCR was done using total RNA from wild-type mouse lung (line 1), transgenic mouse lung (line
2) and PPAP9 cells (line 3). Scg2: secretogranin 2, Chga: chromogranin, Cav-1: caveolin1, Cav-2: caveolin 2, Ascl1: achete-scute complex
homologue 1, Igf-2: insulin-like growth factor 2, FoxA2: forkhead box A2, A, 18S: 18 S ribosomal RNA M: marker.
ABC
Figure 2 Normal lung tissue and transgenic lung tumor histology. (A) Normal lung; original magnification 150×; (B) Transgenic SCLC;
original magnification 150×; (C) Transgenic SCLC; original magnification 400×.
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from the transgenic tumour. Figure 4 and 5 highlight
the expansions of the hierarchical tree containing com-
monly deregulated genes.
Gene network and pathway analysis
We then used Ingenuity Pathways Analysis to highlight
the cellular functions and signaling pathways affected by
the E6/E7 co-expression.
T h ea n a l y s i so f5 3 0 7d i f f e r e n t i a l l ye x p r e s s e dg e n e so f
SCLC transgenic mouse showed that the molecular and
cellular functions primarily affected by the E6/E7 coex-
pression are associated to cellular development, cell
cycle, cellular growth and proliferation. Interestingly, the
analysis of 561 genes differentially expressed in human
SCLC showed the involvemen to ft h es a m em o l e c u l a r
and cellular functions. Furthermore, the top five canoni-
cal pathways affected by the E6/E7 expression based on
their significance, p-value < 0.01, included the Aryl
Hydrocarbon Receptor Signaling, role of BRCA1 in
DNA Damage Response, LPS/IL-1 Mediated Inhibition
of RXR Function, role of CHK Proteins in Cell Cycle
Checkpoint Control and Pyrimidine Metabolism.
Canonical pathway analysis of transgenic SCLC
revealed the Aryl Hydrocarbon Receptor Signaling as
the most significant signaling pathway modulated by E6/
E7 expression (p-value 1.89 × 10
-7). Fifty-one genes in
this pathway were deregulated with 20 of them up-regu-
lated and 31 down-regulated. We used these genes to
assemble the pathway depicted in Figure 6. Fifty-one
deregulated genes out of one hundred fifty-four total
genes that map the canonical pathway Aryl Hydrocar-
bon Receptor Signaling are positioned according to sub-
cellular localization. The genes in this pathway have
ascribed not only to detoxification mechanism, but also
to functions such as cell cycle progression, cancer and
cell proliferation. Cyclin dependent kinase inhibitor 2A
(CDKN2A) occupies a focal position in this pathway;
up-regulation of this gene has been previously suggested
to be a specific marker for dysplastic and neoplastic
epithelial cells of the cervix uteri [21].
In addition, canonical pathways were also evaluated
within the human SCLC. The top five canonical path-
ways modulated in human tumour, based on their sig-
nificance, pvalue < 0.01, included the Metabolism of
Xenobiotics by Cytochrome P450, Pyrimidine Metabo-
lism, Bile Acid Biosynthesis, Aryl Hydrocarbon Receptor
Signaling and Mitotic Roles of Polo-Like Kinase. Evalua-
tion of the results obtained in the two systems showed
deregulation of the same pathways in human SCLC and
in that induced experimentally by the E6/E7 oncopro-
teins of HPV16.
To further highlight the similarity of the two systems,
the comparison analysis is shown in Figure 7 where the
first ten canonical pathways based on their significance
(p-value < 0.01) are reported.
Discussion
Human papillomaviruses (HPVs) are small non-envel-
oped DNA viruses that infect squamous epithelial cells.
HPVs give rise to a large spectrum of epithelial lesions,
mainly benign hyperplasia with low malignant potential.
A subgroup of HPVs, the “high-risk” HPV, is associated
Normal Lung Small Cell Lung Cancer
Figure 3 Human SCLC hierarchical clustering of the significantly
deregulated genes. Analysis show human normal control lung
tissues and SCLC samples. Up-regulated genes are shown in red,
down-regulated genes are shown in green and black bars indicate
not significantly changed genes.
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tion of people infected with high-risk HPV will develop
cancers that usually arise many years after the initial
infection [1].
The high-risk HPV E6 and E7 joint expression is
necessary and sufficient for the immortalization of pri-
mary human keratinocytes in vitro [22]. In squamous
cell carcinomas of the head and neck (HNSCC), the E6
and E7 oncoproteins function through multiple interac-
tions with two cardinal cellular regulators of cell cycle,
the tumor suppressor protein 53 (p53) and the retino-
blastoma gene product (pRb), respectively [23,24].
The E6 protein inactivates p53 by complex formation
or triggering its ubiquitinmediated degradation. The E7
protein inactivates pRb by binding the transcription fac-
tor E2F when pRb is unphosphorylated. Both, pRb phos-
phorylated by cyclindependent kinases and pRb bound
by E7 release the E2F transcription factor, subsequently
leading to progression of the cell into the S-phase [14].
Furthermore, E7 binds to inhibitors of cyclin-dependent
kinases (p16, p21), increasing the level of phosphory-
lated pRb. In this way, HPV 16 oncoproteins induce the
failure of cell cycle regulation with lack of p53 muta-
tions, a common feature of many human cancers [25].
HPV 16/18 are known to cause cervical cancer and has
been suggested to cause vulvar, vaginal and penile can-
cers as well anal cancers [26]. Several laboratories have
demonstrated that HPV DNA could exist in peripheral
blood mononuclear cells (PBMCs) of patients with geni-
tal HPV 16 infection and with cervical cancer. HPV16
genome exists in PBMCs of pediatric HIV patients who
acquired HIV infection via transfusion and in “healthy”
blood donors, suggesting a potential transmission via the
bloodstream [27]. Recent studies suggest that HPV infec-
tion may also play a role in the development of oral can-
cer [28], esophageal cancer [29] and colorectal cancer
[30]. Furthermore the association between the presence
of HPV 16 and the development of head and neck cancer
has been recently established [31]. The possible involve-
ment of HPV in bronchial squamous cell lesions was first
suggested in 1979 by Syrjanen who described epithelial
changes in bronchial carcinomas closely resembling
those of established HPV lesions in the genital tract [7].
HPV 16/18 are established causative role in upper airway
Normal Lung Small Cell Lung Cancer
Figure 4 Expansion of the significantly up-regulated genes human SCLC hierarchical clustering. The expansion highlights the common
up-regulated genes in human SCLC and in SCLC transgenic mouse induced by E6/E7 oncoproteins.
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blood of women with cervical infection, it has been sug-
gested that HPVs can infect the lung through hemato-
genous spread from infected sites [10]. Variability in
reported number of HPV-positive lung cancer may be
explained by several factors, such as environmental vari-
ables, high-risk behavior, genetic susceptibility, and
methodologic approaches with varying sensitivity and
specificity for HPVs identification [32]. The reasons for
having false-negative detection of HPVs are the use of
inappropriate primers or loss of the HPV L1 and E2
genes during integration.
The aim of this study was to identify the molecular
mechanisms commonly deregulated in SCLC induced by
viral oncoproteins and in patients with SCLC. Therefore,
we examined the gene expression profiles of transgenic
mouse model induced by HPV-16 E6/E7 oncoproteins
and compared data with those obtained from human tis-
sues with SCLC. The analysis highlights that several
molecular mechanisms are common to tumor induced
by E6/E7 oncoproteins and human SCLC. In particular,
the Aryl Hydrocarbon receptor signaling is the predomi-
nant pathway deregulated in both systems. The aryl
hydrocarbon receptor (AHR) is a cytosolic ligand-acti-
vated transcription factor that mediates many toxic and
carcinogenic effects in animals and in humans [33]. The
mechanism of action of aryl receptor signaling has been
extensively studied as a function of exposure to TCDD.
Among the results tissue remodelling has been asso-
ciated with its deregulation. In the absence of such
induction, other studies have highlighted the aryl recep-
tor signaling involvement in other pathophysiological
conditions. Outside its well-characterized role, the AHR
also functions as a modulator of cellular signaling
pathways.
AHR can trigger signal transduction pathways
involved in proliferation, differentiation or apoptosis by
mechanisms that may be ligand mediated or comple-
tely ligand independent [34]. Several published
accounts point to a role for AHR in cell cycle control,
although the precise mechanism is still unclear. Two
different signaling pathways contribute to the role of
AHR in cell cycle regulation. AHR promotes apoptosis,
repressing TGFb1 expression by accelerating TGFb1
mRNA degradation [35]. In addition, fibroblasts from
AHR-knockout mice overproduce TGFb1 causing low
Normal Lung Small Cell Lung Cancer
Figure 5 Expansion of the significantly down-regulated genes human SCLC hierarchical clustering. The expansion highlights the
common down-regulated genes in human SCLC and in SCLC transgenic mouse induced by E6/E7 oncoproteins.
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aryl hydrocarbon receptor is a member of transcription
factor controlling a variety of developmental and phy-
siological events including not only drug metabolism
and hence the xenobiotic detoxification but also neu-
rogenesis [33].
Thus, depending on the cellular environment, Ahr
could be considered a pro-proliferative gene in some
cases and an anti-proliferative gene in others. The AHR
ligand-mediated repression of previously active genes
that might have little connection with detoxification
pathways and concomitant induction of previously silent
genes are likely to affect cellular homeostasis.
Protein interaction between AHR and the retinoblas-
toma protein, well know to be inactivated in the SCLC
(Rb/E2F axis) repress S phase gene expression and pre-
vent entry of cells in the S phase [37]. Furthermore,
other members of aryl hydrocarbon receptor signaling,
the inhibitors of cyclin-dependent kinases (p16 and
p21), have been demonstrated to bind E7 increasing the
Figure 6 IPA pathway graphical representation of Aryl Hydrocarbon Receptor Signaling. 51 deregulated genes are represented out of
154. Gene products are positioned according to sub cellular localization. Only direct connections (i.e., direct physical contact between two
molecules) among the individual gene products are shown for clarity of presentation; lines indicate protein-protein binding interactions, and
arrows refer to “acts on” interactions such as proteolysis, expression, and protein-protein interactions. Genes up regulated are shown in red,
down-regulated genes are shown in green.
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evidences of connections between different signal trans-
duction pathways that cross-talk with the AHR suggest-
ing a role of aryl hydrocarbon receptor signaling
deregulation in the SCLC development. We don’t know
if the deregulation of many members of this pathway is
the cause or the effect of SCLC development and the
exact molecular mechanisms by which AHR exerts its
effects remain to be further analyzed.
Finally additional researches are needed to establish
definitive evidence of HPV as an etiological factor of
human SCLC and further proof will be provided by the
impact on the lung cancer incidence of HPV-directed
vaccine meant to prevent cervical cancer.
Figure 7 Comparison analysis of most significant pathways in human SCLC and in SCLC induced by E6/E7. The comparison of top ten
canonical pathways identified by IPA in human SCLC and in transgenic mouse emphasizes the common differential regulation in the tumor
development.
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Using a genome-wide expression analysis of a transgenic
mouse model of SCLC induced by HPV-16 E6/E7 onco-
proteins we tested the hypothesis of a correlation
between HPV infection and lung cancer development.
The analysis led to the identification of several genes
commonly deregulated in the murine model and in
human SCLC. Although we do not provide definitive
proof of direct connection between HPV infection and
SCLC development, our results support the hypothesis
of HPV as a risk factor and/or cofactor in the SCLC
development. Furthermore, the study reveled that the
Aryl Hydrocarbon Receptor Signaling is the primarily
affected pathway by the E6/E7 oncoproteins expression
and that this pathway is also deregulated in human
SCLC. Finally, the identification of molecular mechan-
isms associated to SCLC development induced by HPV
16 oncoproteins and in patients affected by SCLC vali-
date our “in vivo” model and the derived cell line
PPAP9 for the designing and testing new therapeutic
strategies against human SCLC.
Additional material
Additional file 1: Significantly deregulated genes in SCLC induced
by E6/E7 oncoproteins.
Additional file 2: Deregulated genes by the E6/E7 co-expression
associated to neurogenesis.
Additional file 3: RT-PCR primers used to test the expression of
several selected genes to validate the microarray data and
neurogenesis differentiation.
Additional file 4: Human SCLC Deregulated Genes.
Additional file 5: Common deregulated genes in human SCLC and
in E6/E7 induced lung tumor.
Acknowledgements
This work was supported by the Ministero della Salute (Roma), Convenzione
CEINGE-MIUR (2000) art 5.2 (to F.S.), Convenzione CEINGE-Regione Campania
(to F.S.), Progetto S.co.Pe, Centro di eccellenza riconosciuto dal MIUR ex dm
11/2000. We thank Prof. Piero Pucci for a critical reading of the manuscript.
Author details
1CEINGE Biotecnologie Avanzate, Via Comunale Margherita 482, 80145
Napoli, Italy.
2Metabolic and Muscular Unit, Clinic of Paediatric Neurology, A.
O.U Meyer, Viale Pieraccini 6, 50139 Florence, Italy.
3Department of
Physiopathology, Experimental Medicine and Public Health, University of
Siena, 53100 Siena, Italy.
4Department of Biochemistry and Medical
Biotechnologies, University of Naples, “Federico II”, 80131 Naples, Italy.
Authors’ contributions
TB performed the Microarray, RT-PCR experiments and drafted the
manuscript. LC participated in mouse colony maintenance, organ collection
and carried out histopathology analysis. MR contributed to study
conception. RM designed and coordinate the study, carried out microarray
analysis (GeneSpring and IPA software), and wrote the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 September 2010 Accepted: 4 January 2011
Published: 4 January 2011
References
1. Psyrri A, DiMaio D: Human papillomavirus in cervical and head-and neck
cancer. Nat Clin Pract Oncol 2008, 5:24-31.
2. Crum CP, McLachlin CM, Tate JE, Mutter GL: Pathobiology of vulvar
squamous neoplasia. Curr Opin Obstet Gynecol 1997, , 9: 63-69.
3. Kayes O, Ahmed HU, Arya M, Minhas S: Molecular and genetic pathways
in penile cancer. Lancet Oncol 2007, 8:420-429.
4. Syrjänen KJ: HPV infections and oesophageal cancer. J Clin Pathol 2002,
55:721-728.
5. Lyronis ID, Baritaki S, Bizakis I, Tsardi M, Spandidos DA: Evaluation of the
prevalence of human papillomavirus and Epstein-Barr virus in
esophageal squamous cell carcinomas. Int J Biol Markers 2005, 20:5-10.
6. Ostwald C, Rutsatz K, Schweder J, Schmidt W, Gundlach K, Barten M:
Human papillomavirus 6/11 16 and 18 in oral carcinomas and benign
oral lesions. Med Microbiol Immunol 2003, 192:145-148.
7. Syrjanen KJ: Condylomatous changes in neoplastic bronchial epithelium.
Report of a case. Respiration 1979, 38:299-304.
8. Giuliani L, Favalli C, Syrjanen K, Ciotti M: Human papillomavirus infections
in lung cancer. Detection of E6 and E7 transcripts and review of the
literature. Anticancer Res 2007, 27:2697-704.
9. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, et al: The
association of human papillomavirus 16/18 infection with lung cancer
among nonsmoking Taiwanese women. Cancer Res 2001, 61:2799-2803.
10. Chiou HL, Wu MF, Liaw YC, Cheng YW, Wong RH, Chen CY, Lee H: The
presence of human papillomavirus type 16/18 DNA in blood circulation
may act as a risk marker of lung cancer in Taiwan. Cancer 2003,
97:1558-1563.
11. Klein F, Amin Kotb WF, Petersen I: Incidence of human papilloma virus in
lung cancer. Lung Cancer 2009, 65:13-18.
12. Zochbauer-Muller S, Gazdar AF, Minna JD: Molecular pathogenesis of lung
cancer. Annu Rev Physiol 2002, 64:681-708.
13. Syrianen KJ: HPV infections and lung cancer. J Clin Pathol 2002,
55:885-891.
14. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2002, 2:342-350.
15. Carraresi L, Tripodi SA, Mulder LC, Bertini S, Nuti S, Schuerfeld K, et al:
Thymic hyperplasia and lung carcinomas in a line of mice transgenic
for keratin 5-driven HPV16 E6/E7 oncogenes. Oncogene 2001,
20:8148-8153.
16. Carraresi L, Martinelli R, Vannoni A, Riccio M, Dembic M, Tripodi S, et al:
Establishment and characterization of murine small cell lung carcinoma
cell lines derived from HPV-16 E6/E7 transgenic mice. Cancer Lett 2006,
231:65-73.
17. Bélanger MM, Roussel E, Couet J: Caveolin-1 is down-regulated in human
lung carcinoma and acts as a candidate tumor suppressor gene. Chest
2004, 125(5 Suppl):106S.
18. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM,
et al: A primary xenograft model of small-cell lung cancer reveals
irreversible changes in gene expression imposed by culture in vitro.
Cancer Res 2009, 69(8):3364-3373.
19. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al: Loss of
p130 accelerates tumor development in a mouse model for human
small-cell lung carcinoma. Cancer Res 2010, 70(10):3877-3883.
20. Rohrbeck A, Neukirchen J, Rosskopf M, Pardillos GG, Geddert H, Schwalen A,
et al: Gene expression profiling for molecular distinction and
characterization of laser captured primary lung cancers. J Transl Med
2008, 7:6-69.
21. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al:
Overexpression of p16 (INK4A) as a specific marker for dysplastic and
neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001, 92:276-284.
22. Jones EE, Wells SI: Cervical cancer and human papillomaviruses:
inactivation of retinoblastoma and other tumor suppressor pathways.
Curr Mol Med 2006, 6:795-808.
23. Mantovani F, Banks L: The human papillomavirus E6 protein and its
contribution to malignant progression. Oncogene 2001, 20:7874-7887.
24. Munger K, Basile JR, Duensing S: Biological activities and molecular
targets of the human papillomavirus E7 oncoprotein. Oncogene 2001,
20:7888-7898.
Buonomo et al. Journal of Translational Medicine 2011, 9:2
http://www.translational-medicine.com/content/9/1/2
Page 10 of 1125. Jones DL, Alani RM, Munger K: The human papillomavirus E7 oncoprotein
can uncouple cellular differentiation and proliferation in human
keratinocytes by abrogating p 21Cip1-mediated inhibition of cdk2. Genes
Dev 1997, 11:2101-2111.
26. Steenbergen RD, de Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ:
HPV-mediated transformation of the anogenital tract. J Clin Virol 2005,
32:S25-33.
27. Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng ZM: Could
human papillomaviruses be spread through blood? J Clin Microbiol 2005,
43:5428-5434.
28. Anaya-Saavedra G, Ramírez-Amador V, Irigoyen-Camacho ME, Méndez-
Martínez R, García-Carrancá A: High association of human papillomavirus
infection with oral cancer: a case-control study. Arch Med Res 2008,
39:189-197.
29. Wang X, Tian X, Liu F, Zhao Y, Sun M, Chen D, et al: Detection of HPV
DNA in esophageal cancer specimens from different regions and ethnic
groups: a descriptive study. BMC Cancer 2010, 16:10-19.
30. Deschoolmeester V, Van Marck V, Baay M, Weyn C, Vermeulen P, Van
Marck E, et al: Detection of HPV and the role of p16INK4A
overexpression as a surrogate marker for the presence of functional
HPV oncoprotein E7 in colorectal cancer. BMC Cancer 2010, 26;10:117.
31. Marur S, D’Souza G, Westra WH, Forastiere AA: HPV-associated head and
neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010,
11:781-789.
32. Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G: The role of
human papilloma virus in lung cancer: a review of the evidence. Am J
Med Sci 2009, 338:64-67.
33. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A: The aryl
hydrocarbon receptor functions as a tumor suppressor of liver
carcinogenesis. Cancer Res 2010, 70:212-220.
34. Puga A, Xia Y, Elferink C: Role of the aryl hydrocarbon receptor in cell
cycle regulation. Chem Biol Interact 2002, 141:117-130.
35. Chang X, Fan Y, Karyala S, Schwemberger S, Tomlinson CR, Sartor MA, et al:
Ligand-independent regulation of transforming growth factor β1
expression and cell cycle progression by the aryl hydrocarbon receptor.
Mol Cell Biol 2007, 27:6127-6139.
36. Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, Lee KS,
et al: Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon
receptor-null embryo fibroblast. Mol Pharmacol 2000, 57:1056-1063.
37. Marlowe JL, Fan Y, Chang X, Peng L, Knudsen ES, Xia Y, et al: The aryl
hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced
apoptosis. Mol Biol Cell 2008, 19:3263-3271.
doi:10.1186/1479-5876-9-2
Cite this article as: Buonomo et al.: Involvement of aryl hydrocarbon
receptor signaling in the development of small cell lung cancer
induced by HPV E6/E7 oncoproteins. Journal of Translational Medicine
2011 9:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Buonomo et al. Journal of Translational Medicine 2011, 9:2
http://www.translational-medicine.com/content/9/1/2
Page 11 of 11